Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CASP3 | P42574 | 4/20 | 0.60 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.52 |
| ▸ | MDM4 | O15151 | 2/20 | 0.52 |
| ▸ | TP53 | P04637 | 2/20 | 0.52 |
| ▸ | EPHX2 | P34913 | 1/20 | 0.49 |
| ▸ | PIN1 | Q13526 | 1/20 | 0.48 |
| ▸ | MDM2 | Q00987 | 1/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29356434 | 1.00 | CASP3 (0.60) | CASP3KMT2AMDM4TP53EPHX2 | |
| SCHEMBL30307097 | 1.00 | CASP3 (0.60) | CASP3KMT2AMDM4TP53EPHX2 | |
| SCHEMBL120703 | 1.00 | CASP3 (0.60) | CASP3KMT2AMDM4TP53EPHX2 | |
| SCHEMBL799720 | 1.00 | CASP3 (0.60) | CASP3KMT2AMDM4TP53EPHX2 | |
| SCHEMBL178791 | 1.00 | CASP3 (0.60) | CASP3KMT2AMDM4TP53EPHX2 | |
| SCHEMBL29423588 | 1.00 | CASP3 (0.60) | CASP3KMT2AMDM4TP53EPHX2 | |
| SCHEMBL31697682 | 1.00 | CASP3 (0.60) | CASP3KMT2AMDM4TP53EPHX2 | |
| Hydrochloric Acid SCHEMBL6779156 | 0.99 | CASP3 (0.59) | CASP3KMT2AMDM4TP53EPHX2 | |
| Fluoride SCHEMBL7158848 | 0.99 | CASP3 (0.59) | CASP3KMT2AMDM4TP53EPHX2 | |
| SCHEMBL29068310 | 0.95 | CASP3 (0.64) | CASP3KMT2AMDM4TP53EPHX2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 140 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-118937550-A | Method for separating Fmoc-L-Val-OH and Fmoc-D-Val-OH in reverse phase | 贵州医科大学附属医院 | 2024-11-12 | — | — | CN | claimed |
| CN-118829254-A | Perovskite solar cell preparation method and perovskite solar cell | 广东明阳薄膜科技有限公司 | 2024-10-22 | — | — | CN | claimed |
| CN-111333697-B | Synthesis method of romidepsin | 深圳翰宇药业股份有限公司 | 2022-03-08 | — | — | CN | claimed |
| CN-122036842-A | Cathepsin B-sensitive fatty acid-irinotecan prodrug and albumin nanoparticle thereof, and preparation method and application thereof | 沈阳药科大学 | 2026-05-15 | — | — | CN | disclosed |
| EP-4720097-A1 | PEPTIDES WITH LIPOLYTIC, ANTI-LIPOGENIC, ANTIFIBROTIC AND ANTI-INFLAMMATORY ACTIVITY | Fundació Hospital Universitari Vall d'Hebron - Institut de Recerca (ES) | 2026-04-08 | — | — | EP | disclosed |
| EP-3455234-B1 | SECO MACROLIDE COMPOUNDS | SELVITA D O O (HR) | 2026-04-01 | — | — | EP | disclosed |
| US-20260083852-A1 | PROTEOGLYCAN MIMETICS FOR ENHANCED WOUND HEALING, ANGIOGENESIS, AND VASCULAR REPAIR | UNIV CALIFORNIA (US) | 2026-03-26 | — | — | US | disclosed |
| EP-3604326-B1 | PEPTIDE COMPOUND AND METHOD FOR PRODUCING SAME, COMPOSITION FOR SCREENING USE, AND METHOD FOR SELECTING PEPTIDE COMPOUND | FUJIFILM CORP (JP) | 2026-01-07 | — | — | EP | disclosed |
| US-20260001928-A1 | CRF2 RECEPTOR AGONISTS AND THEIR USE IN THERAPY | CORTERIA PHARMACEUTICALS (FR) | 2026-01-01 | — | — | US | disclosed |
| EP-4482578-B1 | CRF2 RECEPTOR AGONISTS AND THEIR USE IN THERAPY | CORTERIA PHARMACEUTICALS (FR) | 2025-12-24 | — | — | EP | disclosed |
| US-12485182-B2 | Proteoglycan mimetics for enhanced wound healing, angiogenesis, and vascular repair | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2025-12-02 | — | — | US | disclosed |
| US-11319347-B2 | Peptide compound and method for producing same, composition for screening use, and method for selecting peptide compound | FUJIFILM CORPORATION (JP) | 2022-05-03 | — | — | US | disclosed |
| WO-2022082006-A1 | BINDING ASSAYS INVOLVING A PLURALITY OF SYNTHETIC COMPOUNDS, TARGETS, AND COUNTER TARGETS | SRI INTERNATIONAL (US) | 2022-04-21 | — | — | WO | disclosed |
| US-20220106361-A1 | MACROCYCLIC COMPOUNDS AND METHODS OF USE THEREOF | GENENTECH, INC. (US) | 2022-04-07 | — | — | US | disclosed |
| EP-3973990-A1 | PROMOTOR FOR PERMEATION INTO CELL LAYER, COMPOSITION FOR FACILITATING DRUG AGENT ABSORPTION, AND PHARMACEUTICAL COMPOSITION | University of Tsukuba (JP) | 2022-03-30 | — | — | EP | disclosed |
| EP-3974563-A1 | CYCLIC PEPTIDES | Chugai Seiyaku Kabushiki Kaisha (JP) | 2022-03-30 | — | — | EP | disclosed |
| WO-2022050529-A1 | COMPOSITION FOR DETECTING OR MEASURING ANALYTE | ㈜베르티스 | 2022-03-10 | — | — | WO | disclosed |
| CN-111333697-B | Synthesis method of romidepsin | 深圳翰宇药业股份有限公司 | 2022-03-08 | — | — | CN | disclosed |
| CN-111333697-B | Synthesis method of romidepsin | 深圳翰宇药业股份有限公司 | 2022-03-08 | — | — | CN | disclosed |
| US-20220041547-A1 | Compounds Useful for Treating a Mannheimia Haemolytica or Histophilus Somni Infection | INTERVET INC. (US) | 2022-02-10 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20220106361-A1 | MACROCYCLIC COMPOUNDS AND METHODS OF USE THEREOF | PAICS, CYCS, LSS | CASP3 53/4885KMT2A 2834/4885MDM4 1699/4885 |
| US-20220041547-A1 | Compounds Useful for Treating a Mannheimia Haemolytica or Histophilus Somni Infection | SORD, HEXD, SNRPD1 | CASP3 2283/4885KMT2A 2327/4885MDM4 2645/4885 |
| US-12485182-B2 | Proteoglycan mimetics for enhanced wound healing, angiogenesis, and vascular repair | PDGFA, PDGFRB, TEK | CASP3 809/4885KMT2A 4334/4885MDM4 4475/4885 |
| US-11319347-B2 | Peptide compound and method for producing same, composition for screening use, and method for selecting peptide compound | VIP, NPPA, NGLY1 | CASP3 2306/4885KMT2A 4395/4885MDM4 4154/4885 |
| US-20260083852-A1 | PROTEOGLYCAN MIMETICS FOR ENHANCED WOUND HEALING, ANGIOGENESIS, AND VASCULAR REPAIR | PDGFA, DCLRE1A, PDGFRA | CASP3 3953/4885KMT2A 2690/4885MDM4 3570/4885 |
| US-20260001928-A1 | CRF2 RECEPTOR AGONISTS AND THEIR USE IN THERAPY | GIPR, NPY2R, NPY1R | CASP3 4474/4885KMT2A 2458/4885MDM4 4186/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.